Cargando…
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
Over the last decade, extensive studies have been made to understand the role played by the mammalian target of rapamycin (mTOR) in cancer. Knowledge in this field has been gained from discoveries in basic research as well as from observations made in patients treated with allosteric mTOR inhibitors...
Autores principales: | Dufour, Marc, Dormond-Meuwly, Anne, Demartines, Nicolas, Dormond, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757428/ https://www.ncbi.nlm.nih.gov/pubmed/24212820 http://dx.doi.org/10.3390/cancers3022478 |
Ejemplares similares
-
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
por: Roulin, Didier, et al.
Publicado: (2011) -
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
por: Blaser, Benjamin, et al.
Publicado: (2012) -
Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
por: Faes, Seraina, et al.
Publicado: (2021) -
Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
por: Faes, Seraina, et al.
Publicado: (2017) -
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
por: Roulin, Didier, et al.
Publicado: (2010)